Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use, PMID: 30402748
Eculizumab: A Review in Generalized Myasthenia Gravis, PMID: 29435915
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder, PMID: 32266705
Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics, PMID: 31703946
When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies, PMID: 30110670
Eculizumab in secondary atypical haemolytic uraemic syndrome, PMID: 28339660
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, PMID: 23738544
Eculizumab in pregnancy: a narrative overview, PMID: 30159857
Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial, PMID: 29685815
Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis, PMID: 27257797
[Eculizumab Treatment for Refractory Generalized Myasthenia Gravis], PMID: 31171753
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis, PMID: 30768680
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience, PMID: 32329881
Eculizumab for the treatment of myasthenia gravis, PMID: 32602752
Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature, PMID: 30598332
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study, PMID: 23623397
Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases, PMID: 30801549
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria, PMID: 16990386
Eculizumab is Efficacious But Often Not Accessible, PMID: 29746439
Eculizumab use in kidney transplantation, PMID: 26536427
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria, PMID: 31949012
Eculizumab, PMID: 18714106
Eculizumab, PMID: 19740388
High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine, PMID: 28704351
Eculizumab, PMID: 17715500
Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review, PMID: 30101319
Eculizumab for treatment of asthma, PMID: 22413827
Eculizumab as a treatment for atypical hemolytic syndrome secondary to carfilzomib, PMID: 29716757
Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria, PMID: 22085388
Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature, PMID: 31520126
Eculizumab in renal transplantation, PMID: 23747093
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria, PMID: 18055865
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis, PMID: 23512355
Eculizumab deposits in vessel walls in thrombotic microangiopathy, PMID: 31345584
Eculizumab: another breakthrough, PMID: 28232621
Eculizumab in Renal Transplantation: A 2017 Update, PMID: 28894081
Treating C3 glomerulopathy with eculizumab, PMID: 29329521
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome, PMID: 24249647
[C5: eculizumab], PMID: 25296873
[Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab], PMID: 30185704
Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence, PMID: 29288280
C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications, PMID: 30032749
Eculizumab in the treatment of membranoproliferative glomerulonephritis, PMID: 25402185
[Myasthenia gravis], PMID: 31538208
Eculizumab: A Complementary addition to existing long-term therapies for myasthenia gravis, PMID: 31074870
The use of eculizumab in renal transplantation, PMID: 23516966
Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases, PMID: 23486421
Atypical Hemolytic Uremic Syndrome, PMID: 29803280
Eculizumab in Acute Motor Axonal Neuropathy: An Ethical Application of an Off-Label Indication, PMID: 32833730
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria, PMID: 25356860
Short-Term Efficacy of Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome., PMID:40531252
Thrombotic Microangiopathy After Kidney Pancreas Transplant Managed With Eculizumab and a Calcineurin Inhibitor-free Basiliximab/Belatacept Maintenance Regimen: Between a Rock and a Hard Place., PMID:40519672
Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies., PMID:40515823
Effectiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome switched from eculizumab: an analysis of a post-marketing surveillance., PMID:40515788
DAGLA autoantibody experience at Mayo Clinic., PMID:40512252
Complement inhibition rapidly blocks lesion extension and facilitates remyelination in neuromyelitis optica., PMID:40506785
Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders., PMID:40506618
Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how., PMID:40505554
[A case of paroxysmal nocturnal hemoglobinuria treated with eculizumab in unintended pregnancy]., PMID:40484825
[Diagnosis, treatment, and genetic analysis of five cases of primary atypical hemolytic uremic syndrome]., PMID:40484823
An updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: Analysis, equipoise, and the urgent need for evidence over anecdote., PMID:40472799
Complement inhibitor therapy as a steroid-sparing strategy in generalized myasthenia gravis., PMID:40453104
From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis., PMID:40447786
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors., PMID:40447351
Case Report: Hematopoietic Stem Cell Transplantation to Treat Severe Acquired Aplastic Anemia in a Pediatric Kidney Transplant Recipient., PMID:40445946
Advances in Research on the Release of von Willebrand Factor from Endothelial Cells through the Membrane Attack Complex C5b-9 in Sepsis., PMID:40438181
Atypical Haemolytic Uraemic Syndrome., PMID:40436118
Hypertensive Emergency and Atypical Hemolytic Uremic Syndrome Associated with Cocaine Use: A Diagnostic and Therapeutic Challenge., PMID:40422585
The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis., PMID:40422242
Perioperative Management of Atypical Hemolytic Uremic Syndrome in a Patient on Maintenance Eculizumab Therapy: A Case Report and Review of the Literature., PMID:40414204
Validation for soluble C5b-9 detection and comparative analysis of three quantification methods., PMID:40412754
Translating biomarker insights into practice: a path forward in TA-TMA management., PMID:40406401
Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Long-term Follow-up and Therapeutic Challenges in a Treatment-Resistant Case., PMID:40398846
Therapeutics controversies in antineutrophilic cytoplasmic antibody-associated vasculitis., PMID:40392453
Atypical hemolytic uremic syndrome: a rare complication of postendoscopic retrograde cholangiopancreatography pancreatitis., PMID:40386314
Kidney transplant in patients with C3 glomerulopathy., PMID:40385590
PLASMIC score to aid diagnosis of aHUS: an analysis of C5 inhibitor clinical trials and the PINC AI™ healthcare database., PMID:40375186
Incidence of infection associated with eculizumab: a meta-analysis of 9 randomized controlled trials., PMID:40356951
Advancements in Complement Inhibition for PNH and Primary Complement Mediated Thrombotic Microangiopathy., PMID:40354320
Comparative efficacy and acceptability of novel biologics in the treatment of myasthenia gravis: systematic review and network meta-analysis of randomized trials., PMID:40346603
Eculizumab in severe pediatric STEC-HUS and its impact on neurological prognosis-a systematic review and meta-analysis., PMID:40341411
Drug-Induced Thrombotic Microangiopathy Arising During the Treatment of Anal Carcinoma After the Use of Mitomycin C., PMID:40330382
Rapid response of eculizumab: a rescue therapy for ventilator-dependent refractory myasthenic crisis., PMID:40327031
Interferon Causes Endothelial Injury in Humans., PMID:40326264
Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease., PMID:40324120
Utility of spinal cord axial-T2 sequence in a population-based cohort of multiple sclerosis., PMID:40301133
Complement dysregulation at lymphatics., PMID:40300720
Correction: A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients., PMID:40299078
Eculizumab as fast-acting rescue therapy for pembrolizumab-induced impending crisis state of myasthenia gravis: a case report., PMID:40297820
Eculizumab as Treatment in Refractory Impeding and Myasthenic Crisis: A Case Series., PMID:40295418
Assessing fall risk in multiple sclerosis using patient-reported outcomes and wearable gait metrics., PMID:40292035
Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria., PMID:40285403
Complement in Antibody-Mediated Rejection of the Kidney Graft: From Pathophysiology to Clinical Practice., PMID:40283639
Dose Adjustments of Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria Undergoing Surgery: A Case Report., PMID:40276419
Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment., PMID:40273330
Neuromyelitis optica spectrum disorder in Latin America: a global data share initiative., PMID:40267692
Treatment of atypical hemolytic uremic syndrome with eculizumab in a patient presenting with neuropsychiatric prodrome: a case report., PMID:40264782
Late Relapse After Autologous Hematopoietic Stem Cell Transplantation in AQP4-IgG-Positive NMOSD., PMID:40257801
The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment., PMID:40257298
Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center., PMID:40255570
For research use only. Not for human or drug use.
